Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Breast Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 502 articles:
HTML format

Single Articles

    June 2024
  1. JORIS S, Giron P, Olsen C, Seneca S, et al
    Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers.
    BMC Cancer. 2024;24:723.
    PubMed     Abstract available

  2. XU C, Sun L, Wang H, Sun J, et al
    Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification.
    BMC Cancer. 2024;24:726.
    PubMed     Abstract available

  3. KANG Z, Jin Y, Yu H, Li S, et al
    Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:708.
    PubMed     Abstract available

  4. LI Y, Han D, Shen C
    Prediction of the axillary lymph-node metastatic burden of breast cancer by (18)F-FDG PET/CT-based radiomics.
    BMC Cancer. 2024;24:704.
    PubMed     Abstract available

  5. XU JX, Zhu QL, Bi YM, Peng YC, et al
    New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.
    BMC Cancer. 2024;24:691.
    PubMed     Abstract available

  6. YE J, Ying J, Chen H, Wu Z, et al
    PPIH acts as a potential predictive biomarker for patients with common solid tumors.
    BMC Cancer. 2024;24:681.
    PubMed     Abstract available

    May 2024
  7. AZIZ MA, Chowdhury S, Jafrin S, Barek MA, et al
    Genetic association of Interleukin-17A polymorphism in Bangladeshi patients with breast and cervical cancer: a case-control study with functional analysis.
    BMC Cancer. 2024;24:660.
    PubMed     Abstract available

  8. YU S, Yue Z, Liu Q
    Pectinose induces cell cycle arrest in luminal A and triple-negative breast cancer cells by promoting autophagy through activation of the p38 MAPK signaling pathway.
    BMC Cancer. 2024;24:639.
    PubMed     Abstract available

  9. KUEMMEL S, Harper-Wynne C, Park YH, Franke F, et al
    heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-po
    BMC Cancer. 2024;24:641.
    PubMed     Abstract available

  10. LAMBERT V, Kane S, Howidi B, Nguyen BN, et al
    Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    BMC Cancer. 2024;24:631.
    PubMed     Abstract available

  11. ZHENG M, Wu L, Xiao R, Cai J, et al
    Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation.
    BMC Cancer. 2024;24:619.
    PubMed     Abstract available

  12. WANG Q, Chen H, Yang Q, Qiu J, et al
    Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study.
    BMC Cancer. 2024;24:610.
    PubMed     Abstract available

  13. EL HABRE R, Aoun R, Tahtouh R, Hilal G, et al
    All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
    BMC Cancer. 2024;24:615.
    PubMed     Abstract available

  14. BOUTRUS RR, Abdelazim YA, Mohammed T, Bayomy M, et al
    The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
    BMC Cancer. 2024;24:599.
    PubMed     Abstract available

  15. HAUNER D, Mang A, Donik L, Schederecker F, et al
    Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.
    BMC Cancer. 2024;24:591.
    PubMed     Abstract available

  16. SAHU RK, Tandon S, Singh S, Das BC, et al
    Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells.
    BMC Cancer. 2024;24:566.
    PubMed     Abstract available

  17. SBAITY E, Tamim H, El-Hajj Fuleihan G, Abbas J, et al
    Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study.
    BMC Cancer. 2024;24:560.
    PubMed     Abstract available

  18. WANG J, Tian C, Zheng BJ, Zhang J, et al
    The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
    BMC Cancer. 2024;24:549.
    PubMed     Abstract available

    April 2024
  19. HAN JY, Che N, Mo J, Zhang DF, et al
    Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
    BMC Cancer. 2024;24:532.
    PubMed     Abstract available

  20. ZOU J, Chen Q, He Y, Pan Y, et al
    Systematic optimization and evaluation of culture conditions for the construction of circulating tumor cell clusters using breast cancer cell lines.
    BMC Cancer. 2024;24:507.
    PubMed     Abstract available

  21. GILL J, Yendamuri K, Chatterjee U, Yao S, et al
    Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
    BMC Cancer. 2024;24:461.
    PubMed     Abstract available

  22. LIU Z, Li J, Zhao F, Ren D, et al
    Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
    BMC Cancer. 2024;24:440.
    PubMed     Abstract available

  23. LI B, Dai S, Wang Q, Jing H, et al
    Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis.
    BMC Cancer. 2024;24:409.
    PubMed     Abstract available

  24. WU Z, Zhang Q, Jin Y, Zhang X, et al
    Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
    BMC Cancer. 2024;24:411.
    PubMed     Abstract available

  25. QIU C, Wang W, Xu S, Li Y, et al
    Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer.
    BMC Cancer. 2024;24:402.
    PubMed     Abstract available

    March 2024
  26. ESMAT E, Haidary AM, Saadaat R, Rizvi SN, et al
    Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
    BMC Cancer. 2024;24:388.
    PubMed     Abstract available

  27. ZAHEDI H, Alizadeh-Dibazari Z, Mirghafourvand M, Sahebihagh MH, et al
    The effectiveness of couple-based interventions on the marital outcomes of women with genital and breast cancer and their partners: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:391.
    PubMed     Abstract available

  28. CHEHELGERDI M, Khorramian-Ghahfarokhi M, Dehkordi FB, Chehelgerdi M, et al
    Comment on "A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer".
    BMC Cancer. 2024;24:377.
    PubMed     Abstract available

  29. HUANG W, Wang C, Shen Y, Chen Q, et al
    Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    BMC Cancer. 2024;24:378.

  30. REN H, Wang Z, Zhang L, Zhu G, et al
    Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
    BMC Cancer. 2024;24:367.
    PubMed     Abstract available

  31. WANG Y, Men X, Gu Y, Wang H, et al
    Retraction Note: Haplotype analysis on correlation between transcription factor 7-like 2 gene polymorphism and breast cancer risk.
    BMC Cancer. 2024;24:366.

  32. CHANDRAN G, Tang N, Ngo ELP, Huang S, et al
    Comparing the efficacy of a multi-dimensional breast cancer rehabilitation programme versus a home-based exercise programme during adjuvant cancer treatment.
    BMC Cancer. 2024;24:361.
    PubMed     Abstract available

  33. LOFT LH, Pedersen LH, Bigaard J, Bojesen SE, et al
    Attitudes towards risk-stratified breast cancer screening: a population-based survey among 5,001 Danish women.
    BMC Cancer. 2024;24:347.
    PubMed     Abstract available

  34. WANG ZQ, Wu ZX, Wang ZP, Bao JX, et al
    Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis.
    BMC Cancer. 2024;24:353.
    PubMed     Abstract available

  35. OPUTA CH, Peters E, Otovwe A
    Effect of educational intervention on the knowledge, attitude and practice of breast self-examination among female students at a private university in Southern Nigeria.
    BMC Cancer. 2024;24:355.
    PubMed     Abstract available

  36. BOULIFA A, Raftery MJ, Franzen AS, Radecke C, et al
    Role of beta-(1-->3)(1-->6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
    BMC Cancer. 2024;24:339.
    PubMed     Abstract available

  37. KNUDSEN BM, Sondergaard SR, Stacey D, Steffensen KD, et al
    Impact of timing and format of patient decision aids for breast cancer patients on their involvement in and preparedness for decision making - the IMPACTT randomised controlled trial protocol.
    BMC Cancer. 2024;24:336.
    PubMed     Abstract available

  38. MAENPAA N, Tiainen L, Hamalainen M, Luukkaala T, et al
    Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
    BMC Cancer. 2024;24:331.
    PubMed     Abstract available

  39. PALMER S, Blomqvist C, Holmqvist M, Lindman H, et al
    Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry.
    BMC Cancer. 2024;24:329.
    PubMed     Abstract available

  40. KANG D, Wang C, Han Z, Zheng L, et al
    Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer.
    BMC Cancer. 2024;24:318.
    PubMed     Abstract available

  41. GOH SP, Ong SC, Chan JE
    Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.
    BMC Cancer. 2024;24:316.
    PubMed     Abstract available

  42. SHITRIT IB, Wang A, Ilan K, Agassi R, et al
    Epidemiological, clinical, and pathological characteristics of invasive breast cancer in Bedouin and Jewish women in southern Israel: a retrospective comparative study.
    BMC Cancer. 2024;24:310.
    PubMed     Abstract available

  43. KHANNA D, Sharma P, Budukh A, Vishwakarma R, et al
    Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry.
    BMC Cancer. 2024;24:308.
    PubMed     Abstract available

  44. MOLIERE S, Lodi M, Leblanc S, Gressel A, et al
    MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.
    BMC Cancer. 2024;24:295.
    PubMed     Abstract available

  45. MESHKANI Z, Moradi N, Aboutorabi A, Farabi H, et al
    A cost-benefit analysis of genetic screening test for breast cancer in Iran.
    BMC Cancer. 2024;24:279.
    PubMed     Abstract available

  46. REN J, Chen W, Zhou Y, Sun J, et al
    The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.
    BMC Cancer. 2024;24:278.
    PubMed     Abstract available

    February 2024
  47. ABEDI M, Sahebi L, Eslami B, Saberi A, et al
    Using a combination of superb microvascular imaging and other auxiliary ultrasound techniques to increase the accuracy of gray-scale ultrasound for breast masses.
    BMC Cancer. 2024;24:224.
    PubMed     Abstract available

  48. BEN-ZION BERLINER M, Yust-Katz S, Lavie I, Goldberg Y, et al
    Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
    BMC Cancer. 2024;24:219.
    PubMed     Abstract available

  49. LABEDZ N, Anisiewicz A, Stachowicz-Suhs M, Banach J, et al
    Dual effect of vitamin D(3) on breast cancer-associated fibroblasts.
    BMC Cancer. 2024;24:209.
    PubMed     Abstract available

  50. ZHANG Y, Song M, Yang Z, Huang X, et al
    Healthy lifestyles, systemic inflammation and breast cancer risk: a mediation analysis.
    BMC Cancer. 2024;24:208.
    PubMed     Abstract available

  51. HUANG X, Yu Y, Luo S, Fu W, et al
    Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on >/= 1 line of endocrine therapy: systematic review and meta-analysis.
    BMC Cancer. 2024;24:205.

  52. SU MX, Lin HW, Nguyen HTH, Lin TC, et al
    Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
    BMC Cancer. 2024;24:195.
    PubMed     Abstract available

  53. KIM MW, Lee H, Lee S, Moon S, et al
    Drug-resistant profiles of extracellular vesicles predict therapeutic response in TNBC patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:185.
    PubMed     Abstract available

  54. JIANG Y, Liu J, Chen L, Qian Z, et al
    A promising target for breast cancer: B7-H3.
    BMC Cancer. 2024;24:182.
    PubMed     Abstract available

  55. LU Y, Hui B, Yang D, Li Y, et al
    Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients.
    BMC Cancer. 2024;24:181.
    PubMed     Abstract available

  56. ABBOAH-OFFEI M, Bayuo J, Salifu Y, Afolabi O, et al
    Experiences and perceptions of men following breast cancer diagnosis: a mixed method systematic review.
    BMC Cancer. 2024;24:179.
    PubMed     Abstract available

  57. ZHANG Y, Guan Y, Zheng X, Li C, et al
    Hypoxia-induced miR-181a-5p up-regulation reduces epirubicin sensitivity in breast cancer cells through inhibiting EPDR1/TRPC1 to activate PI3K/AKT signaling pathway.
    BMC Cancer. 2024;24:167.
    PubMed     Abstract available

    January 2024
  58. WEAVER KE, Dressler EV, Smith S, Nightingale CL, et al
    Cardiovascular health assessment in routine cancer follow-up in community settings: survivor risk awareness and perspectives.
    BMC Cancer. 2024;24:158.
    PubMed     Abstract available

  59. GOLESTAN A, Tahmasebi A, Maghsoodi N, Faraji SN, et al
    Unveiling promising breast cancer biomarkers: an integrative approach combining bioinformatics analysis and experimental verification.
    BMC Cancer. 2024;24:155.
    PubMed     Abstract available

  60. BELAID I, Baya MF, Ben Ayed S, Ben Ayed A, et al
    Transcutaneous canine breast cancer detection in Tunisia: a pilot study.
    BMC Cancer. 2024;24:151.
    PubMed     Abstract available

  61. YANG ZJ, Xin F, Chen ZJ, Yu Y, et al
    Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.
    BMC Cancer. 2024;24:134.
    PubMed     Abstract available

  62. LEE YH, Huang CY, Hsieh YH, Yang CH, et al
    A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens.
    BMC Cancer. 2024;24:121.
    PubMed     Abstract available

  63. SHAO H, Sun Y, Na Z, Jing H, et al
    Diagnostic value of applying preoperative breast ultrasound and clinicopathologic features to predict axillary lymph node burden in early invasive breast cancer: a study of 1247 patients.
    BMC Cancer. 2024;24:112.
    PubMed     Abstract available

  64. DOWLING GP, Toomey S, Bredin P, Parker I, et al
    Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
    BMC Cancer. 2024;24:91.
    PubMed     Abstract available

  65. KHAJOEI R, Azadeh P, ZohariAnboohi S, Ilkhani M, et al
    Breast cancer survivorship needs: a qualitative study.
    BMC Cancer. 2024;24:96.
    PubMed     Abstract available

  66. IDO M, Fujii K, Mishima H, Kubo A, et al
    Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.
    BMC Cancer. 2024;24:85.
    PubMed     Abstract available

  67. SKARPING I, Ellbrant J, Dihge L, Ohlsson M, et al
    Retrospective validation study of an artificial neural network-based preoperative decision-support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN14341750).
    BMC Cancer. 2024;24:86.
    PubMed     Abstract available

  68. SCHANTZ C, Coulibaly A, Traore A, Traore BA, et al
    Access to oncology care in Mali: a qualitative study on breast cancer.
    BMC Cancer. 2024;24:81.
    PubMed     Abstract available

  69. WONDIMAGEGNEHU A, Teferra S, Assefa M, Zebrack B, et al
    "How can a woman live without having a breast?": challenges related to mastectomy in Ethiopia.
    BMC Cancer. 2024;24:60.
    PubMed     Abstract available

  70. TONG Y, Zhou T, Wang X, Deng S, et al
    Upregulation of CENPM promotes breast carcinogenesis by altering immune infiltration.
    BMC Cancer. 2024;24:54.
    PubMed     Abstract available

  71. GAO H, Ouyang D, Guan X, Xu J, et al
    Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.
    BMC Cancer. 2024;24:50.
    PubMed     Abstract available

  72. GREGOIRE C, Baussard L, Ernst M, Diep A, et al
    Evaluation of a psychoneurological symptom cluster in patients with breast or digestive cancer: a longitudinal observational study.
    BMC Cancer. 2024;24:51.
    PubMed     Abstract available

  73. RANJBAR A, Zangouri V, Shokripour M
    Margin status impact on recurrence of phyllodes tumors in high-risk groups: a retrospective observational study.
    BMC Cancer. 2024;24:48.
    PubMed     Abstract available

  74. ZHANG L, Mei X, Hu Z, Yu B, et al
    Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial.
    BMC Cancer. 2024;24:49.
    PubMed     Abstract available

  75. WANG R, Wang Y, Fang L, Xie Y, et al
    Efficacy and safety of traditional Chinese medicine in the treatment of menopause-like syndrome for breast cancer survivors: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:42.
    PubMed     Abstract available

  76. HUANG W, Wang C, Shen Y, Chen Q, et al
    A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    BMC Cancer. 2024;24:39.
    PubMed     Abstract available

  77. SETIAWAN L, Graef K, Schmolze D, Alem A, et al
    Building pathology capacity in sub-Saharan Africa to improve breast cancer diagnosis and treatment: training laboratory technicians in high-quality manual immunohistochemistry.
    BMC Cancer. 2024;24:32.
    PubMed     Abstract available

  78. XU X, Zhao W, Liu C, Gao Y, et al
    The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:13.
    PubMed     Abstract available

  79. WANG W, Lei W, Fang Z, Jiang R, et al
    Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.
    BMC Cancer. 2024;24:1.
    PubMed     Abstract available

  80. ZHAO S, Miao M, Wang Q, Zhao H, et al
    The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
    BMC Cancer. 2024;24:30.
    PubMed     Abstract available

  81. XUE X, Guo L, Guo C, Li L, et al
    Proficiency testing of diagnosis in histopathology and immunohistochemistry of breast pathology in China: results from a pilot work of National Single Disease Quality Control Program for breast cancer.
    BMC Cancer. 2024;24:23.
    PubMed     Abstract available

  82. GHASEMIAN M, Zehtabi M, Dari MAG, Pour FK, et al
    The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers.
    BMC Cancer. 2024;24:4.
    PubMed     Abstract available

  83. HUANG X, Yu Y, Luo S, Fu W, et al
    The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on >/= 1 line of endocrine therapy: systematic review and meta-analysis.
    BMC Cancer. 2024;24:21.
    PubMed     Abstract available

  84. CHOULLI F, Tafenzi HA, Hattimy FE, Choulli MK, et al
    Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study : Mohammed VI University Hospital, Medical Oncology Department, Marrakech, Morocco.
    BMC Cancer. 2024;24:17.
    PubMed     Abstract available

    December 2023
  85. YANG L, Gu Y, Wang B, Sun M, et al
    A multivariable model of ultrasound and clinicopathological features for predicting axillary nodal burden of breast cancer: potential to prevent unnecessary axillary lymph node dissection.
    BMC Cancer. 2023;23:1264.
    PubMed     Abstract available

  86. YAO K, Xiaojun Z, Tingxiao Z, Shiyao L, et al
    Correction: Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer.
    BMC Cancer. 2023;23:1265.

  87. CHEN MN, Fang ZX, Wu Z, Bai JW, et al
    Notch3 restricts metastasis of breast cancers through regulation of the JAK/STAT5A signaling pathway.
    BMC Cancer. 2023;23:1257.
    PubMed     Abstract available

  88. NAHHAT F, Doyya M, Zabad K, Laban TA, et al
    Breast cancer quality of care in Syria: screening, diagnosis, and staging.
    BMC Cancer. 2023;23:1234.
    PubMed     Abstract available

  89. WANG L, Jiang C, Wang N, Wen YL, et al
    "Moderate" adjuvant chemotherapy-induced leukopenia is beneficial for survival of patients with early breast cancer: a retrospective study.
    BMC Cancer. 2023;23:1227.
    PubMed     Abstract available

  90. TASFA MARINE B, Mengistie DT
    Application of parametric survival analysis to women patients with breast cancer at Jimma University Medical Center.
    BMC Cancer. 2023;23:1223.
    PubMed     Abstract available

  91. LV YF, Zhang H, Cui Z, Ma CJ, et al
    Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2.
    BMC Cancer. 2023;23:1220.
    PubMed     Abstract available

  92. SOLEIMANI M, Ayyoubzadeh SM, Jalilvand A, Ghazisaeedi M, et al
    Exploring the geospatial epidemiology of breast cancer in Iran: identifying significant risk factors and spatial patterns for evidence-based prevention strategies.
    BMC Cancer. 2023;23:1219.
    PubMed     Abstract available

  93. YAO K, Xiaojun Z, Tingxiao Z, Shiyao L, et al
    Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer.
    BMC Cancer. 2023;23:1213.
    PubMed     Abstract available

  94. LI F, Wang J, Yan YQ, Bai CZ, et al
    CD147 promotes breast cancer migration and invasion by inducing epithelial-mesenchymal transition via the MAPK/ERK signaling pathway.
    BMC Cancer. 2023;23:1214.
    PubMed     Abstract available

  95. DAI D, Wu H, Zhuang H, Chen R, et al
    Genetic and clinical landscape of ER + /PR- breast cancer in China.
    BMC Cancer. 2023;23:1189.
    PubMed     Abstract available

  96. ELIA C, de Girolamo L, Clarisse B, Galin M, et al
    Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocol.
    BMC Cancer. 2023;23:1178.
    PubMed     Abstract available

  97. YIN Y, Tong L, Wan Z, Sui Y, et al
    CYP4B1 polymorphisms and the risk of breast cancer in Chinese women: a case-control study.
    BMC Cancer. 2023;23:1177.
    PubMed     Abstract available

  98. YU F, Li L, Zhang M, Sun S, et al
    Correction: Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
    BMC Cancer. 2023;23:1176.

  99. KUZIEL G, Moore BN, Haugstad GP, Xiong Y, et al
    Alterations in the mammary gland and tumor microenvironment of formerly obese mice.
    BMC Cancer. 2023;23:1183.
    PubMed     Abstract available

    November 2023
  100. ZHU QM, Li HX, Ma PQ, Wu LX, et al
    A potential immunotherapy target for breast cancer: parenchymal and immune-stromal expression of the NLRP3 inflammasome pathway.
    BMC Cancer. 2023;23:1163.
    PubMed     Abstract available

  101. JACOBSEN S, Glavind-Kristensen M, Jensen AB, Forman A, et al
    Vaginal CO(2) laser therapy for genitourinary syndrome in breast cancer survivors-VagLaser study protocol: a randomized blinded, placebo-controlled trial.
    BMC Cancer. 2023;23:1164.
    PubMed     Abstract available

  102. LI L, Zhang H, Wang L, Xie C, et al
    Optimization of supraclavicular lymph node clinical target volume delineation in high-risk breast cancer: a single center experience and recommendation.
    BMC Cancer. 2023;23:1168.
    PubMed     Abstract available

  103. EMAD B, WalyEldeen AA, Hassan H, Sharaky M, et al
    Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.
    BMC Cancer. 2023;23:1151.
    PubMed     Abstract available

  104. JAVADI M, Sazegar H, Doosti A
    Genome editing approaches with CRISPR/Cas9: the association of NOX4 expression in breast cancer patients and effectiveness evaluation of different strategies of CRISPR/Cas9 to knockout Nox4 in cancer cells.
    BMC Cancer. 2023;23:1155.
    PubMed     Abstract available

  105. LIU CJ, Zhang L, Sun Y, Geng L, et al
    Application of CT and MRI images based on an artificial intelligence algorithm for predicting lymph node metastasis in breast cancer patients: a meta-analysis.
    BMC Cancer. 2023;23:1134.
    PubMed     Abstract available

  106. LUNDO K, Dmytriyeva O, Spohr L, Goncalves-Alves E, et al
    Lactate receptor GPR81 drives breast cancer growth and invasiveness through regulation of ECM properties and Notch ligand DLL4.
    BMC Cancer. 2023;23:1136.
    PubMed     Abstract available

  107. FAUSER D, Rimalis-Vogt E, Mattes J, Bethge M, et al
    Psychological interventions during breast cancer rehabilitation: a randomized controlled trial comparing structured short-term psychotherapy versus non-specific group discussion.
    BMC Cancer. 2023;23:1133.
    PubMed     Abstract available

  108. KLAASSEN-DEKKER A, Drossaert CHC, Van Maaren MC, Van Leeuwen-Stok AE, et al
    Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design.
    BMC Cancer. 2023;23:1112.
    PubMed     Abstract available

  109. HE H, Wang S, Zhang W, Gao S, et al
    Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells.
    BMC Cancer. 2023;23:1101.
    PubMed     Abstract available

  110. NAJAFI S, Ansari M, Omidi Z, Olfatbakhsh A, et al
    Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial.
    BMC Cancer. 2023;23:1093.
    PubMed     Abstract available

  111. MA L, Yang Y, Ma J, Mao L, et al
    Correlation between AI-based CT organ features and normal lung dose in adjuvant radiotherapy following breast-conserving surgery: a multicenter prospective study.
    BMC Cancer. 2023;23:1085.
    PubMed     Abstract available

  112. DROUYER A, Beaussire L, Jorda P, Leheurteur M, et al
    Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
    BMC Cancer. 2023;23:1061.
    PubMed     Abstract available

  113. EL-GAMAL R, Elfarrash S, El-Nablaway M, Salem AA, et al
    Anti-proliferative activity of RIHMS-Qi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases.
    BMC Cancer. 2023;23:1053.
    PubMed     Abstract available

  114. FENTIE H, Ntenda PAM, Tiruneh FN
    Dietary pattern and other factors of breast cancer among women: a case control study in Northwest Ethiopia.
    BMC Cancer. 2023;23:1050.
    PubMed     Abstract available

    October 2023
  115. FELDMAN D, Sinberger LA, Salmon-Divon M, Ben-Dror J, et al
    Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors.
    BMC Cancer. 2023;23:1031.
    PubMed     Abstract available

  116. LI Y, Han D, Shen C, Duan X, et al
    Construction of a comprehensive predictive model for axillary lymph node metastasis in breast cancer: a retrospective study.
    BMC Cancer. 2023;23:1028.
    PubMed     Abstract available

  117. KOTEPUI K, Kotepui M, Majima HJ, Tangpong J, et al
    Association between NDRG1 protein expression and aggressive features of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1003.
    PubMed     Abstract available

  118. NAGASAKA M, Zhang SS, Baca Y, Xiu J, et al
    Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
    BMC Cancer. 2023;23:1000.
    PubMed     Abstract available

  119. CHEN D, Wang Q, Dong M, Chen F, et al
    Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution.
    BMC Cancer. 2023;23:984.
    PubMed     Abstract available

  120. TUGRAL A, Aribas Z, Akyol M, Bakar Y, et al
    Assessment of sensorimotor and strength related function of breast cancer patients during systemic drug therapy: a prospective observational study.
    BMC Cancer. 2023;23:981.
    PubMed     Abstract available

  121. WANG Z, Ren H, Zhu G, Zhang L, et al
    High expression of CCDC69 is correlated with immunotherapy response and protective effects on breast cancer.
    BMC Cancer. 2023;23:974.
    PubMed     Abstract available

  122. YAN H, Ren W, Jia M, Xue P, et al
    Breast cancer risk factors and mammographic density among 12518 average-risk women in rural China.
    BMC Cancer. 2023;23:952.
    PubMed     Abstract available

  123. YU F, Li L, Zhang M, Sun S, et al
    Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
    BMC Cancer. 2023;23:948.
    PubMed     Abstract available

    The impact of an online educational game on breast cancer awareness among university female students, Malaysia: a pilot study.
    BMC Cancer. 2023;23:947.
    PubMed     Abstract available

  125. JAHROMI MK, Tehrani AN, Farhadnejad H, Emamat H, et al
    Dietary advanced glycation end products are associated with an increased risk of breast cancer in Iranian adults.
    BMC Cancer. 2023;23:932.
    PubMed     Abstract available

  126. WANG J, Huang J, Ding H, Ma J, et al
    Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer.
    BMC Cancer. 2023;23:929.
    PubMed     Abstract available

    September 2023
  127. YANG X, Li Y, Lu X, Ren X, et al
    Clinicopathological features and prognosis of patients with HER2-low breast cancer.
    BMC Cancer. 2023;23:914.
    PubMed     Abstract available

  128. FANG T, Zhang Z, Zhou H, Wu W, et al
    Effect of genetic liability to migraine and its subtypes on breast cancer: a mendelian randomization study.
    BMC Cancer. 2023;23:887.
    PubMed     Abstract available

  129. DIVOUX J, Florent R, Jacobs M, Lequesne J, et al
    The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
    BMC Cancer. 2023;23:883.
    PubMed     Abstract available

  130. SAWHNEY R, Nathani P, Patil P, Bhandarkar P, et al
    Recognising socio-cultural barriers while seeking early detection services for breast cancer: a study from a Universal Health Coverage setting in India.
    BMC Cancer. 2023;23:881.
    PubMed     Abstract available

  131. MYERS C, Waldron C, Bennett K, Cahir C, et al
    Impact of the COVID-19 pandemic on women living with and beyond breast cancer: a qualitative study of women's experiences and how they varied by social determinants of health.
    BMC Cancer. 2023;23:867.
    PubMed     Abstract available

  132. JIANG K, Zhou D, Xu F, Xia W, et al
    Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes.
    BMC Cancer. 2023;23:869.
    PubMed     Abstract available

  133. KUO SH, Tseng LM, Chen ST, Sagara Y, et al
    Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
    BMC Cancer. 2023;23:865.
    PubMed     Abstract available

  134. JOSHY G, Khalatbari-Soltani S, Soga K, Butow P, et al
    Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
    BMC Cancer. 2023;23:774.
    PubMed     Abstract available

  135. HEINZE F, Czwikla J, Heinig M, Langner I, et al
    German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data.
    BMC Cancer. 2023;23:852.
    PubMed     Abstract available

  136. GUI Z, Tian Y, Yu T, Liu S, et al
    Clinical implications and immune features of CENPN in breast cancer.
    BMC Cancer. 2023;23:851.
    PubMed     Abstract available

  137. ZHU M, Li X, Feng Y, Jia T, et al
    Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study.
    BMC Cancer. 2023;23:845.
    PubMed     Abstract available

  138. CHEN HL, Huang FB, Chen Q, Deng YC, et al
    Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers.
    BMC Cancer. 2023;23:841.
    PubMed     Abstract available

  139. RYU S, Yoon SH, Song J, Choi Y, et al
    Impact of media compositions and culture systems on the immunophenotypes of patient-derived breast cancer cells.
    BMC Cancer. 2023;23:831.
    PubMed     Abstract available

    August 2023
  140. LIU Y, Wu J, Ji Z, Chen L, et al
    Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
    BMC Cancer. 2023;23:816.
    PubMed     Abstract available

  141. LI Y, Wu X, Yan Y, Zhou P, et al
    Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer.
    BMC Cancer. 2023;23:813.
    PubMed     Abstract available

  142. JI D, Luo Y, Wang J, Chen S, et al
    CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
    BMC Cancer. 2023;23:805.
    PubMed     Abstract available

  143. FENG Z, Yang X, Tian M, Zeng N, et al
    BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis.
    BMC Cancer. 2023;23:807.
    PubMed     Abstract available

  144. LIU N, Kang Y, Qu N, Kong C, et al
    Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study.
    BMC Cancer. 2023;23:801.
    PubMed     Abstract available

  145. CORTES J, Haiderali A, Huang M, Pan W, et al
    Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2023;23:792.
    PubMed     Abstract available

  146. KJELDSTED E, Ammitzboll G, Jorgensen LB, Lodin A, et al
    Neo-train: study protocol and feasibility results for a two-arm randomized controlled trial investigating the effect of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer.
    BMC Cancer. 2023;23:777.
    PubMed     Abstract available

  147. WU Q, Tao X, Luo Y, Zheng S, et al
    A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer.
    BMC Cancer. 2023;23:776.
    PubMed     Abstract available

  148. BARTHOLOMEW K, Ghafel M, Tin Tin S, Aye PS, et al
    Receipt of mastectomy and adjuvant radiotherapy following breast conserving surgery (BCS) in New Zealand women with BCS-eligible breast cancer, 2010-2015: an observational study focusing on ethnic differences.
    BMC Cancer. 2023;23:766.
    PubMed     Abstract available

  149. ZHOU M, Gan XL, Ren YX, Chen QX, et al
    AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer.
    BMC Cancer. 2023;23:743.
    PubMed     Abstract available

  150. OFVERHOLM A, Torngren T, Rosen A, Arver B, et al
    Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    BMC Cancer. 2023;23:738.
    PubMed     Abstract available

  151. GERNIER F, Grellard JM, Dupont C, Castel H, et al
    Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.
    BMC Cancer. 2023;23:736.
    PubMed     Abstract available

    July 2023
  152. PARIKH P, Babu G, Singh R, Krishna V, et al
    Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.
    BMC Cancer. 2023;23:714.
    PubMed     Abstract available

  153. AFSHAR-BAKSHLOO M, Albers S, Richter C, Berninger O, et al
    How breast cancer therapies impact body image - real-world data from a prospective cohort study collecting patient-reported outcomes.
    BMC Cancer. 2023;23:705.
    PubMed     Abstract available

  154. MITCHELL H, Mclean J, Gavin AT, Visser O, et al
    Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland.
    BMC Cancer. 2023;23:700.
    PubMed     Abstract available

  155. JIANG Y, Zhang J, Zhong J, Liao H, et al
    Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    BMC Cancer. 2023;23:702.
    PubMed     Abstract available

  156. CHITRANGI S, Vaity P, Jamdar A, Bhatt S, et al
    Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
    BMC Cancer. 2023;23:689.
    PubMed     Abstract available

  157. MERTENS E, Barrenechea-Pulache A, Sagastume D, Vasquez MS, et al
    Understanding the contribution of lifestyle in breast cancer risk prediction: a systematic review of models applicable to Europe.
    BMC Cancer. 2023;23:687.
    PubMed     Abstract available

  158. VEYSSIERE H, Dressaire M, Pete R, Pinard C, et al
    RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire.
    BMC Cancer. 2023;23:679.
    PubMed     Abstract available

  159. YANG X, Xu Y, Fu J, Shen Z, et al
    Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer.
    BMC Cancer. 2023;23:680.
    PubMed     Abstract available

  160. ZEELST LJV, Ten Wolde B, Plate JDJ, Volders JH, et al
    The QUILT study: quilting sutures in patients undergoing breast cancer surgery: a stepped wedge cluster randomized trial study.
    BMC Cancer. 2023;23:667.
    PubMed     Abstract available

  161. LAMMINMAKI M, Leivonen A, Heinavaara S, Nygard M, et al
    A population-based cohort study on changes in breast, lung and colorectal cancer incidence and mortality among non-Western immigrant women.
    BMC Cancer. 2023;23:665.
    PubMed     Abstract available

  162. MCNAMEE N, Catalano M, Mukhopadhya A, O'Driscoll L, et al
    An extensive study of potential inhibitors of extracellular vesicles release in triple-negative breast cancer.
    BMC Cancer. 2023;23:654.
    PubMed     Abstract available

  163. CAI M, Li M, Lv H, Zhou S, et al
    HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases.
    BMC Cancer. 2023;23:656.
    PubMed     Abstract available

  164. MAO X, Omeogu C, Karanth S, Joshi A, et al
    Association of reproductive risk factors and breast cancer molecular subtypes: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:644.
    PubMed     Abstract available

  165. CARRACA EV, Rodrigues B, Franco S, Nobre I, et al
    Promoting physical activity through supervised vs motivational behavior change interventions in breast cancer survivors on aromatase inhibitors (PAC-WOMAN): protocol for a 3-arm pragmatic randomized controlled trial.
    BMC Cancer. 2023;23:632.
    PubMed     Abstract available

  166. GUNTHER M, Hentschel L, Schuler M, Muller T, et al
    Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.
    BMC Cancer. 2023;23:629.
    PubMed     Abstract available

  167. ELIASSEN FM, Blafjelldal V, Helland T, Hjorth CF, et al
    Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review.
    BMC Cancer. 2023;23:625.
    PubMed     Abstract available

  168. SHI Y, Qiu Z, Yu J, Li Z, et al
    Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study.
    BMC Cancer. 2023;23:615.
    PubMed     Abstract available

    June 2023
  169. FOLDI J, Tsagianni A, Salganik M, Schnabel CA, et al
    Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.
    BMC Cancer. 2023;23:606.
    PubMed     Abstract available

  170. HALLSSON LR, Sroczynski G, Engel J, Siebert U, et al
    Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.
    BMC Cancer. 2023;23:590.
    PubMed     Abstract available

  171. FAN R, Wang L, Bu X, Wang W, et al
    Unmet supportive care needs of breast cancer survivors: a systematic scoping review.
    BMC Cancer. 2023;23:587.
    PubMed     Abstract available

  172. HUANG Q, Mo J, Yang H, Ji Y, et al
    Analysis of m7G-Related signatures in the tumour immune microenvironment and identification of clinical prognostic regulators in breast cancer.
    BMC Cancer. 2023;23:583.
    PubMed     Abstract available

  173. RYU JM, Lee J, Lee J, Ko B, et al
    Mastectomy with Reconstruction Including Robotic Endoscopic Surgery (MARRES): a prospective cohort study of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG) and Korean Breast Cancer Study Group (KBCSG).
    BMC Cancer. 2023;23:571.
    PubMed     Abstract available

  174. KANG YJ, Yoon CI, Yang YJ, Baek JM, et al
    A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
    BMC Cancer. 2023;23:570.
    PubMed     Abstract available

  175. CHRISTAKOUDI S, Tsilidis KK, Dossus L, Rinaldi S, et al
    A body shape index (ABSI) is associated inversely with post-menopausal progesterone-receptor-negative breast cancer risk in a large European cohort.
    BMC Cancer. 2023;23:562.
    PubMed     Abstract available

  176. XIE Y, Hu T, Chen R, Chang H, et al
    Predicting acute radiation dermatitis in breast cancer: a prospective cohort study.
    BMC Cancer. 2023;23:537.
    PubMed     Abstract available

  177. COUTURAUD F, Mahe I, Schmidt J, Gleize JC, et al
    Adult breast, lung, pancreatic, upper and lower gastrointestinal cancer patients with hospitalized venous thromboembolism in the national French hospital discharge database.
    BMC Cancer. 2023;23:531.
    PubMed     Abstract available

  178. CHEN J, Li Z, Han Z, Kang D, et al
    Prognostic value of tumor necrosis based on the evaluation of frequency in invasive breast cancer.
    BMC Cancer. 2023;23:530.
    PubMed     Abstract available

  179. HUO Q, Wang J, Xie N
    High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis.
    BMC Cancer. 2023;23:501.
    PubMed     Abstract available

  180. CORCORAN L, Friedenreich CM, McNeely ML, Culos-Reed NS, et al
    A qualitative study examining newly diagnosed breast cancer patients' experiences of participating in the Alberta Moving Beyond Breast Cancer (AMBER) prospective cohort study.
    BMC Cancer. 2023;23:500.
    PubMed     Abstract available

  181. PASCETTA SA, Kirsh SM, Cameron M, Uniacke J, et al
    Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling.
    BMC Cancer. 2023;23:494.
    PubMed     Abstract available

  182. POURNABEE M, Keshavarz-Fathi M, Esmaeili P, Mahdavi Sharif P, et al
    Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
    BMC Cancer. 2023;23:495.
    PubMed     Abstract available

    May 2023
  183. LIN Y, Zhao Y, Chen M, Li Z, et al
    CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.
    BMC Cancer. 2023;23:479.
    PubMed     Abstract available

  184. LI G, Sun Y, Huang Y, Lian J, et al
    Fusobacterium nucleatum-derived small extracellular vesicles facilitate tumor growth and metastasis via TLR4 in breast cancer.
    BMC Cancer. 2023;23:473.
    PubMed     Abstract available

  185. AKANDA MR, Ahn EJ, Kim YJ, Salam SMA, et al
    Analysis of stromal PDGFR-beta and alpha-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
    BMC Cancer. 2023;23:468.
    PubMed     Abstract available

  186. SHARMA N, Ng AY, James JJ, Khara G, et al
    Multi-vendor evaluation of artificial intelligence as an independent reader for double reading in breast cancer screening on 275,900 mammograms.
    BMC Cancer. 2023;23:460.
    PubMed     Abstract available

  187. CAO M, Lu H, Yan S, Pang H, et al
    Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
    BMC Cancer. 2023;23:463.
    PubMed     Abstract available

  188. TAKANO EA, Younes MM, Meehan K, Spalding L, et al
    Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
    BMC Cancer. 2023;23:459.
    PubMed     Abstract available

  189. DROZD C, Curtit E, Jacquinot Q, Marquine C, et al
    A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.
    BMC Cancer. 2023;23:449.
    PubMed     Abstract available

  190. YAO L, Li Y, Li S, Wang M, et al
    ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer.
    BMC Cancer. 2023;23:440.
    PubMed     Abstract available

  191. YAMADA Y, Simon R, Iwane K, Nakanishi Y, et al
    An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9.
    BMC Cancer. 2023;23:438.
    PubMed     Abstract available

  192. ZHANG J, Wu Q, Yin W, Yang L, et al
    Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients.
    BMC Cancer. 2023;23:431.
    PubMed     Abstract available

  193. PAKIET A, Jedrzejewska A, Duzowska K, Waclawska A, et al
    Serum fatty acid profiles in breast cancer patients following treatment.
    BMC Cancer. 2023;23:433.
    PubMed     Abstract available

  194. CIVIL YA, Oei AL, Duvivier KM, Bijker N, et al
    Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.
    BMC Cancer. 2023;23:419.
    PubMed     Abstract available

  195. ZHAO C, Zeng N, Zhou X, Tan Y, et al
    CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3.
    BMC Cancer. 2023;23:392.
    PubMed     Abstract available

    April 2023
  196. HAYAMA S, Nakamura R, Ishige T, Sangai T, et al
    The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
    BMC Cancer. 2023;23:384.
    PubMed     Abstract available

  197. DAI X, Cai L, Zhang Z, Li J, et al
    SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity.
    BMC Cancer. 2023;23:376.
    PubMed     Abstract available

  198. ZHANG W, Lin S, Zeng B, Chen X, et al
    High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients.
    BMC Cancer. 2023;23:377.
    PubMed     Abstract available

  199. AN Y, Fnu G, Xie C, Weber GF, et al
    Meta-analysis of Osteopontin splice variants in cancer.
    BMC Cancer. 2023;23:373.
    PubMed     Abstract available

  200. POMEY MP, Nelea MI, Normandin L, Vialaron C, et al
    An exploratory cross-sectional study of the effects of ongoing relationships with accompanying patients on cancer care experience, self-efficacy, and psychological distress.
    BMC Cancer. 2023;23:369.
    PubMed     Abstract available

  201. BASSI N, Hovland HN, Rasheed K, Jarhelle E, et al
    Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays.
    BMC Cancer. 2023;23:368.
    PubMed     Abstract available

  202. LIU X, Sun K, Yang H, Xia L, et al
    Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study.
    BMC Cancer. 2023;23:361.
    PubMed     Abstract available

  203. LI J
    Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer.
    BMC Cancer. 2023;23:353.
    PubMed     Abstract available

  204. BENZON B, Marijan S, Pervan M, Cikes Culic V, et al
    Eta polycaprolactone (epsilon-PCL) implants appear to cause a partial differentiation of breast cancer lung metastasis in a murine model.
    BMC Cancer. 2023;23:343.
    PubMed     Abstract available

  205. MELKI R, Melloul M, Aissaoui S, El Harroudi T, et al
    Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    BMC Cancer. 2023;23:339.
    PubMed     Abstract available

  206. CHEN Y, Xie Y, Li B, Shao H, et al
    Automated Breast Ultrasound (ABUS)-based radiomics nomogram: an individualized tool for predicting axillary lymph node tumor burden in patients with early breast cancer.
    BMC Cancer. 2023;23:340.
    PubMed     Abstract available

  207. MA SJ, Gill J, Yendamuri K, Chatterjee U, et al
    Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
    BMC Cancer. 2023;23:330.
    PubMed     Abstract available

  208. PRIEUR A, Harper A, Khan M, Vire B, et al
    Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort.
    BMC Cancer. 2023;23:305.
    PubMed     Abstract available

  209. LIU S, Ye Z, Xue VW, Sun Q, et al
    KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
    BMC Cancer. 2023;23:307.
    PubMed     Abstract available

  210. FAN L, Sui XY, Jin X, Zhang WJ, et al
    High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
    BMC Cancer. 2023;23:298.
    PubMed     Abstract available

    March 2023
  211. SONG C, Shang F, Tu W, Liu X, et al
    Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
    BMC Cancer. 2023;23:296.
    PubMed     Abstract available

  212. BARUA D, Sultana A, Islam MN, Cox F, et al
    RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    BMC Cancer. 2023;23:288.
    PubMed     Abstract available

  213. DEUTSCHMANN C, Singer CF, Gschwantler-Kaulich D, Pfeiler G, et al
    Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer".
    BMC Cancer. 2023;23:281.
    PubMed     Abstract available

  214. JIAN FX, Bao PX, Li WF, Cui YH, et al
    Negative regulation of CD44st by miR-138-5p affects the invasive ability of breast cancer cells and patient prognosis after breast cancer surgery.
    BMC Cancer. 2023;23:269.
    PubMed     Abstract available

  215. WANG Y, Du L, Jing J, Zhao X, et al
    Leptin and leptin receptor expression as biomarkers for breast cancer: a retrospective study.
    BMC Cancer. 2023;23:260.
    PubMed     Abstract available

  216. LIU E, Zhang F, Xu T, Ye L, et al
    Relationship between tumor microbiota transcriptional activity and gene expression in breast cancer.
    BMC Cancer. 2023;23:252.
    PubMed     Abstract available

  217. ZHANG C, Qi L, Cai J, Wu H, et al
    Clinicomics-guided distant metastasis prediction in breast cancer via artificial intelligence.
    BMC Cancer. 2023;23:239.
    PubMed     Abstract available

  218. MA R, Wei W, Ye H, Dang C, et al
    A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2023;23:245.
    PubMed     Abstract available

  219. TAKADA K, Kashiwagi S, Iimori N, Kouhashi R, et al
    Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer.
    BMC Cancer. 2023;23:224.
    PubMed     Abstract available

  220. SANDAMALI JAN, Hewawasam RP, Fernando MACSS, Jayatilaka KAPW, et al
    Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka.
    BMC Cancer. 2023;23:210.
    PubMed     Abstract available

  221. MA Y, Lv M, Yuan P, Chen X, et al
    Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2023;23:208.
    PubMed     Abstract available

  222. RYU J, Lee EY, Min J, Yeon S, et al
    Effect of a 1-year tailored exercise program according to cancer trajectories in patients with breast cancer: study protocol for a randomized controlled trial.
    BMC Cancer. 2023;23:200.
    PubMed     Abstract available

    February 2023
  223. KARACIN C, Oksuzoglu B, Demirci A, Keskinkilic M, et al
    Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
    BMC Cancer. 2023;23:192.

  224. LUO J, Kibriya MG, Chen H, Kim K, et al
    A metabolome-wide case-control study of african american breast cancer patients.
    BMC Cancer. 2023;23:183.
    PubMed     Abstract available

  225. SHI Q, Yu J, Liu D, Ren F, et al
    Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
    BMC Cancer. 2023;23:173.
    PubMed     Abstract available

  226. RASHA F, Boligala GP, Yang MV, Martinez-Marin D, et al
    Dishevelled 2 regulates cancer cell proliferation and T cell mediated immunity in HER2-positive breast cancer.
    BMC Cancer. 2023;23:172.
    PubMed     Abstract available

  227. RASHED A, Fitzpatrick OM, Easty DJ, Coyne Z, et al
    An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer.
    BMC Cancer. 2023;23:171.
    PubMed     Abstract available

  228. AL-KEILANI MS, Bdeir R, Elstaty RI, Alqudah MA, et al
    Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
    BMC Cancer. 2023;23:158.
    PubMed     Abstract available

  229. VOLKEL V, Steinger B, Koller M, Klinkhammer-Schalke M, et al
    Colorectal cancer survivors' long-term recollections of their illness and therapy up to seven years after enrolment into a randomised controlled clinical trial.
    BMC Cancer. 2023;23:149.
    PubMed     Abstract available

  230. KARACIN C, Oksuzoglu B, Demirci A, Keskinkilic M, et al
    Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
    BMC Cancer. 2023;23:136.
    PubMed     Abstract available

  231. GHEYBI E, Asoodeh A, Amani J
    Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice.
    BMC Cancer. 2023;23:134.
    PubMed     Abstract available

  232. CHEN X, Zhang J, Lei X, Yang L, et al
    CD1C is associated with breast cancer prognosis and immune infiltrates.
    BMC Cancer. 2023;23:129.
    PubMed     Abstract available

  233. AFAYA A, Laari TT, Seidu AA, Afaya RA, et al
    Factors associated with the uptake of clinical breast examination among women of reproductive age in Lesotho: analysis of a national survey.
    BMC Cancer. 2023;23:114.
    PubMed     Abstract available

    January 2023
  234. PIVOT X, Manikhas AG, Shamrai V, Dzagnidze G, et al
    Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.
    BMC Cancer. 2023;23:112.
    PubMed     Abstract available

  235. YANG J, Zhao B, Ling X, Li D, et al
    Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
    BMC Cancer. 2023;23:103.
    PubMed     Abstract available

  236. SHAO Z, Yu J, Cheng Y, Ma W, et al
    MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer.
    BMC Cancer. 2023;23:97.
    PubMed     Abstract available

  237. JIA Z, Dai M, Shang Y, Li Y, et al
    Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy.
    BMC Cancer. 2023;23:93.
    PubMed     Abstract available

  238. ZHOU S, Lv H, Li A, Li M, et al
    A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio >/= 2.0 and an average HER2 copy number < 4.0 per cell in China.
    BMC Cancer. 2023;23:84.
    PubMed     Abstract available

  239. LIEDE A, Sebby W, Miriyala AKR, Potluri R, et al
    Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
    BMC Cancer. 2023;23:78.
    PubMed     Abstract available

  240. TAN Z, Zou Y, Zhu M, Luo Z, et al
    Correction: Carnitine palmitoyl transferase 1 A is a novel diagnostic and predictive biomarker for breast cancer.
    BMC Cancer. 2023;23:40.

  241. ZHANG C, Liang Z, Liu W, Zeng X, et al
    Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
    BMC Cancer. 2023;23:37.
    PubMed     Abstract available

  242. VERBEEK JGE, de Jong VMT, Wijnja HM, Jager A, et al
    High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.
    BMC Cancer. 2023;23:26.
    PubMed     Abstract available

  243. DENG H, Wang L, Wang N, Zhang K, et al
    Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data.
    BMC Cancer. 2023;23:29.
    PubMed     Abstract available

  244. HUANG S, Yang Q, Zheng X, Chow KM, et al
    Predictors of surgery choices in women with early-stage breast cancer in China: a retrospective study.
    BMC Cancer. 2023;23:23.
    PubMed     Abstract available

  245. LIU S, Du S, Gao S, Teng Y, et al
    A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients.
    BMC Cancer. 2023;23:15.
    PubMed     Abstract available

  246. NAFISSI N, Meshkati Yazd SM, Shahriarirad R, Zangeneh S, et al
    Postoperative cosmetic outcome of intraoperative radiotherapy in comparison to whole breast radiotherapy in early stage breast cancer; a retrospective cohort study.
    BMC Cancer. 2023;23:9.
    PubMed     Abstract available

    December 2022
  247. ZIMBALIST AS, Caan BJ, Chen WY, Mittendorf EA, et al
    Metabolic abnormalities and survival among patients with non-metastatic breast cancer.
    BMC Cancer. 2022;22:1361.
    PubMed     Abstract available

  248. YANG H, Xu L, Guan S, Hao X, et al
    Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
    BMC Cancer. 2022;22:1357.
    PubMed     Abstract available

  249. QI WX, Cao L, Zheng S, Xu C, et al
    IMNI PRECISION trial protocol: a phase II, open-label, non-inferior randomized controlled trial of tailoring omission of internal mammary node irradiation for early-stage breast cancer.
    BMC Cancer. 2022;22:1356.
    PubMed     Abstract available

  250. BEATTY L, Kemp E, Butow P, Girgis A, et al
    Finding My Way-Advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial.
    BMC Cancer. 2022;22:1353.
    PubMed     Abstract available

  251. ALLAHYARI A, Ehsanpour A, Najafi B, Ansarinejad N, et al
    Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
    BMC Cancer. 2022;22:1348.

  252. MAHTANI R, Niyazov A, Arondekar B, Lewis K, et al
    Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from th
    BMC Cancer. 2022;22:1343.
    PubMed     Abstract available

  253. YAO H, Li N, Yuan H
    Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
    BMC Cancer. 2022;22:1337.
    PubMed     Abstract available

  254. KLAESTAD E, Opdahl S, Raj SX, Bofin AM, et al
    Long term trends of breast cancer incidence according to proliferation status.
    BMC Cancer. 2022;22:1340.
    PubMed     Abstract available

  255. ZHANG GY, Zhang R, Bai P, Li SM, et al
    Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    BMC Cancer. 2022;22:1331.
    PubMed     Abstract available

  256. GENG SK, Fu SM, Zhang HW, Fu YP, et al
    Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer.
    BMC Cancer. 2022;22:1328.
    PubMed     Abstract available

  257. BRUAND M, Salleron J, Guihard S, Crety CM, et al
    Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort.
    BMC Cancer. 2022;22:1318.
    PubMed     Abstract available

  258. SIRAIT LMF, Hamajima N, Suzuki Y, Wahyuningsih ES, et al
    Factors associated with positive cancer screening for the uterine cervix and breast in Jakarta Province, Indonesia: a cross-sectional study.
    BMC Cancer. 2022;22:1309.
    PubMed     Abstract available

  259. TERASHIMA T, Konishi H, Sato Y, Igarashi M, et al
    Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: a nationwide study.
    BMC Cancer. 2022;22:1303.
    PubMed     Abstract available

  260. BODARD S, Lassalle L, Larousserie F, Guinebert S, et al
    Performance of Sonoelastography for predicting malignancy in soft tissue.
    BMC Cancer. 2022;22:1305.
    PubMed     Abstract available

  261. VOUTILAINEN S, Heikkila P, Bartkova J, Nevanlinna H, et al
    Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of gammaH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
    BMC Cancer. 2022;22:1298.
    PubMed     Abstract available

  262. ZHU P, Liu G, Wang X, Lu J, et al
    Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis.
    BMC Cancer. 2022;22:1283.
    PubMed     Abstract available

  263. LI M, Zheng Y, Li X, Shen X, et al
    ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer.
    BMC Cancer. 2022;22:1280.
    PubMed     Abstract available

  264. YOUSEFI H, Bahramy A, Zafari N, Delavar MR, et al
    Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer.
    BMC Cancer. 2022;22:1282.
    PubMed     Abstract available

  265. GORMAN LS, Ruane H, Woof VG, Southworth J, et al
    The co-development of personalised 10-year breast cancer risk communications: a 'think-aloud' study.
    BMC Cancer. 2022;22:1264.
    PubMed     Abstract available

  266. XU D, Xu N, Sun L, Yang Z, et al
    TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway.
    BMC Cancer. 2022;22:1267.
    PubMed     Abstract available

  267. PAIK HJ, Kim SJ, Kim KS, Kim Y, et al
    Characteristics and chronologically changing patterns of late-onset breast cancer in Korean women of age >/= 70 years: A hospital based-registry study.
    BMC Cancer. 2022;22:1261.
    PubMed     Abstract available

  268. DE LA CRUZ-MERINO L, Gion M, Cruz J, Alonso-Romero JL, et al
    Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.
    BMC Cancer. 2022;22:1258.
    PubMed     Abstract available

  269. DRAGVOLL I, Bofin AM, Soiland H, Taraldsen G, et al
    Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer.
    BMC Cancer. 2022;22:1247.
    PubMed     Abstract available

  270. JIANG C, Xiu Y, Yu X, Qiao K, et al
    Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.
    BMC Cancer. 2022;22:1249.
    PubMed     Abstract available

  271. LIANG X, Chen X, Yang Z, Liao Y, et al
    Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer.
    BMC Cancer. 2022;22:1250.
    PubMed     Abstract available

    November 2022
  272. MENG X, Li W, Meng Z, Li Y, et al
    EIF4A3-induced circBRWD3 promotes tumorigenesis of breast cancer through miR-142-3p_miR-142-5p/RAC1/PAK1 signaling.
    BMC Cancer. 2022;22:1225.
    PubMed     Abstract available

  273. URAS C, Cabioglu N, Tokat F, Er O, et al
    Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up.
    BMC Cancer. 2022;22:1217.
    PubMed     Abstract available

  274. FREITAS-JUNIOR R, de Oliveira VM, Frasson AL, Cavalcante FP, et al
    Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology.
    BMC Cancer. 2022;22:1201.
    PubMed     Abstract available

  275. SAXTON JM, Pickering K, Wane S, Humphreys H, et al
    Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer.
    BMC Cancer. 2022;22:1202.
    PubMed     Abstract available

  276. JM S, K P, S W, H C, et al
    The experiences and perceptions of female breast cancer patients regarding weight management during and after treatment for oestrogen-receptor positive disease: a qualitative study.
    BMC Cancer. 2022;22:1189.
    PubMed     Abstract available

  277. MEYER D, Pastor-Villaescusa B, Michel S, Hauner H, et al
    Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials.
    BMC Cancer. 2022;22:1187.
    PubMed     Abstract available

  278. KE L, Li S, Cui H
    The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:1185.
    PubMed     Abstract available

  279. LEE TH, Chang JH, Jang BS, Kim JS, et al
    Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy.
    BMC Cancer. 2022;22:1179.
    PubMed     Abstract available

  280. SHANG C, Chen Q, Zu F, Ren W, et al
    Integrated analysis identified prognostic microRNAs in breast cancer.
    BMC Cancer. 2022;22:1170.
    PubMed     Abstract available

  281. XIONG J, Zuo W, Wu Y, Wang X, et al
    Ultrasonography and clinicopathological features of breast cancer in predicting axillary lymph node metastases.
    BMC Cancer. 2022;22:1155.
    PubMed     Abstract available

  282. DITSATHAM C, Sripan P, Chaiwun B, Klunklin P, et al
    Breast Cancer Subtypes in Northern Thailand and Barriers to satisfactory survival outcomes.
    BMC Cancer. 2022;22:1147.
    PubMed     Abstract available

  283. SHARMNI VISHNU K, Win TT, Aye SN, Basavaraj AK, et al
    Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
    BMC Cancer. 2022;22:1139.
    PubMed     Abstract available

  284. XU T, Zhang SM, Wu HM, Wen XM, et al
    Prognostic significance of prognostic nutritional index and systemic immune-inflammation index in patients after curative breast cancer resection: a retrospective cohort study.
    BMC Cancer. 2022;22:1128.
    PubMed     Abstract available

  285. LI Y, Chen L, Lv J, Chen X, et al
    Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
    BMC Cancer. 2022;22:1125.
    PubMed     Abstract available

  286. ROGINSKI M, Sifaki-Pistolla D, Stomby A, Velivasaki G, et al
    Paradoxes of breast cancer incidence and mortality in two corners of Europe.
    BMC Cancer. 2022;22:1123.
    PubMed     Abstract available

  287. DE ALMEIDA MARQUES BERNABE R, de Souza Vieira M, Felicio de Souza V, Gomes Fontana L, et al
    Muscle strength is associated with fracture risk obtained by fracture risk assessment tool (FRAX) in women with breast cancer.
    BMC Cancer. 2022;22:1115.
    PubMed     Abstract available

    October 2022
  288. DEUTSCHMANN C, Bartsch R, Singer CF, Gschwantler-Kaulich D, et al
    Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria.
    BMC Cancer. 2022;22:1099.
    PubMed     Abstract available

  289. YAN D, Ju X, Luo B, Guan F, et al
    Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer.
    BMC Cancer. 2022;22:1082.
    PubMed     Abstract available

  290. CHERIFI F, Da Silva A, Johnson A, Blanc-Fournier C, et al
    HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    BMC Cancer. 2022;22:1081.
    PubMed     Abstract available

  291. NABI-MEYBODI M, Sahebnasagh A, Hakimi Z, Shabani M, et al
    Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial.
    BMC Cancer. 2022;22:1079.
    PubMed     Abstract available

  292. HAYNES BM, Cunningham K, Shekhar MPV
    RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    BMC Cancer. 2022;22:1073.
    PubMed     Abstract available

  293. LIU L, Zhai W, Wang F, Yu L, et al
    Using machine learning to identify gene interaction networks associated with breast cancer.
    BMC Cancer. 2022;22:1070.
    PubMed     Abstract available

  294. KORONKIEWICZ M, Kazimierczuk Z, Orzeszko A
    Antitumor activity of the protein kinase inhibitor 1-(beta-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.
    BMC Cancer. 2022;22:1069.
    PubMed     Abstract available

  295. ISMAIL AL-KHALIL W, Al-Salhi L, Rijjal S, Aljamali M, et al
    The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
    BMC Cancer. 2022;22:1067.
    PubMed     Abstract available

  296. DI BENEDETTO C, Oh J, Choudhery Z, Shi W, et al
    NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer.
    BMC Cancer. 2022;22:1056.
    PubMed     Abstract available

  297. HAWKINS R, McWilliams L, Ulph F, Evans DG, et al
    Healthcare professionals' views following implementation of risk stratification into a national breast cancer screening programme.
    BMC Cancer. 2022;22:1058.
    PubMed     Abstract available

  298. ZHANG J, Dong D, Wei Q, Ren L, et al
    CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma.
    BMC Cancer. 2022;22:1052.
    PubMed     Abstract available

  299. WONG CHONG E, Joncas FH, Seidah NG, Calon F, et al
    Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
    BMC Cancer. 2022;22:1049.
    PubMed     Abstract available

  300. LEICHSENRING J, Vladimirova V, Solbach C, Karn T, et al
    EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
    BMC Cancer. 2022;22:1040.
    PubMed     Abstract available

  301. ZHANG L, She R, Zhu J, Lu J, et al
    Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer.
    BMC Cancer. 2022;22:1030.
    PubMed     Abstract available

    September 2022
  302. MCNAMEE N, de la Fuente LR, Santos-Martinez MJ, O'Driscoll L, et al
    Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation.
    BMC Cancer. 2022;22:1023.
    PubMed     Abstract available

  303. PIEK MW, de Boer JP, van Duijnhoven F, van der Wal JE, et al
    The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.
    BMC Cancer. 2022;22:1018.
    PubMed     Abstract available

  304. JEON Y, Jo U, Hong J, Gong G, et al
    Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
    BMC Cancer. 2022;22:1014.
    PubMed     Abstract available

  305. FONSECA MM, Alhassan T, Nisha Y, Koszycki D, et al
    Correction: Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
    BMC Cancer. 2022;22:1009.

  306. LINDMAN H, Wiklund F, Andersen KK
    Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
    BMC Cancer. 2022;22:1006.
    PubMed     Abstract available

  307. GONG M, Liu X, Zhao X, Wang H, et al
    A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation.
    BMC Cancer. 2022;22:1005.
    PubMed     Abstract available

  308. ARTHUR EK, Menon U, Reese JB, Browning K, et al
    Profiles of women's adjustment after cancer based on sexual and psychosocial wellbeing: results of a cluster analysis.
    BMC Cancer. 2022;22:1003.
    PubMed     Abstract available

  309. JIANG Y, Wang B, Li JK, Li SY, et al
    Collagen fiber features and COL1A1: are they associated with elastic parameters in breast lesions, and can COL1A1 predict axillary lymph node metastasis?
    BMC Cancer. 2022;22:1004.
    PubMed     Abstract available

  310. FILLBRUNN M, Signorovitch J, Andre F, Wang I, et al
    PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
    BMC Cancer. 2022;22:1002.
    PubMed     Abstract available

  311. HAJJ A, Khoury R, Hachem R, Awad A, et al
    Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the "CAGE-Cog" study.
    BMC Cancer. 2022;22:996.
    PubMed     Abstract available

  312. MCCLELLAN B, Gries P, Harlow B, Tiziani S, et al
    An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer.
    BMC Cancer. 2022;22:976.
    PubMed     Abstract available

  313. AL SAAD S, Al Shenawi H, Almarabheh A, Al Shenawi N, et al
    Is laterality in breast Cancer still worth studying? Local experience in Bahrain.
    BMC Cancer. 2022;22:968.
    PubMed     Abstract available

  314. ALLAHYARI A, Ehsanpour A, Ansarinejad N, Mehrzad V, et al
    Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
    BMC Cancer. 2022;22:960.
    PubMed     Abstract available

  315. PEPE FF, Cazzaniga ME, Baroni S, Riva F, et al
    Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 stu
    BMC Cancer. 2022;22:956.
    PubMed     Abstract available

  316. WANG Y, Lu R, Chen P, Cui R, et al
    Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers.
    BMC Cancer. 2022;22:951.
    PubMed     Abstract available

  317. JIANG Y, Mason M, Cho Y, Chittiprolu A, et al
    Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
    BMC Cancer. 2022;22:950.
    PubMed     Abstract available

    August 2022
  318. MAHMOOD D, Ahmad A, Sharif F, Arslan SA, et al
    Clinical application of low-level laser therapy (Photo-biomodulation therapy) in the management of breast cancer-related lymphedema: a systematic review.
    BMC Cancer. 2022;22:937.
    PubMed     Abstract available

  319. WANG Q, Li B, Liu Z, Shang H, et al
    Prediction model of axillary lymph node status using automated breast ultrasound (ABUS) and ki-67 status in early-stage breast cancer.
    BMC Cancer. 2022;22:929.
    PubMed     Abstract available

  320. XU H, Zhang H, Guo W, Zhong X, et al
    Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
    BMC Cancer. 2022;22:923.
    PubMed     Abstract available

  321. XU H, Qi Z, Zhao Q, Xue J, et al
    Lentinan enhances the antitumor effects of Delta-like 1 via neutrophils.
    BMC Cancer. 2022;22:918.
    PubMed     Abstract available

  322. GETU MA, Chen C, Wang P, Kantelhardt EJ, et al
    Quality of life and its influencing factors among breast cancer patients at Tikur Anbessa specialised hospital, Addis Ababa, Ethiopia.
    BMC Cancer. 2022;22:897.
    PubMed     Abstract available

  323. NSAFUL J, Dedey F, Nartey E, Labi J, et al
    The impact of a breast cancer educational intervention in Ghanaian high schools.
    BMC Cancer. 2022;22:893.
    PubMed     Abstract available

  324. ZHANG K, Chen L, Zheng H, Zeng Y, et al
    Cytokines secreted from adipose tissues mediate tumor proliferation and metastasis in triple negative breast cancer.
    BMC Cancer. 2022;22:886.
    PubMed     Abstract available

  325. FONTVIEILLE E, His M, Biessy C, Navionis AS, et al
    Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study.
    BMC Cancer. 2022;22:877.
    PubMed     Abstract available

  326. ALNOUMAS L, van den Driest L, Apczynski Z, Lannigan A, et al
    Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets.
    BMC Cancer. 2022;22:874.
    PubMed     Abstract available

  327. XU A, Chu X, Zhang S, Zheng J, et al
    Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma.
    BMC Cancer. 2022;22:872.
    PubMed     Abstract available

  328. SHEN K, Yao L, Zhu J, Gu X, et al
    Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
    BMC Cancer. 2022;22:863.
    PubMed     Abstract available

  329. LI L, Li F, Hu X, Wu Z, et al
    LAP3 contributes to IFN-gamma-induced arginine depletion and malignant transformation of bovine mammary epithelial cells.
    BMC Cancer. 2022;22:864.
    PubMed     Abstract available

  330. CUSTODIO IDD, Nunes FSM, Lima MTM, de Carvalho KP, et al
    Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy.
    BMC Cancer. 2022;22:860.
    PubMed     Abstract available

  331. LIU PH, Wei JC, Wang YH, Yeh MH, et al
    Female breast cancer incidence predisposing risk factors identification using nationwide big data: a matched nested case-control study in Taiwan.
    BMC Cancer. 2022;22:849.
    PubMed     Abstract available

  332. KWON YJ, Seo EB, Jeong AJ, Lee SH, et al
    The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2022;22:852.
    PubMed     Abstract available

  333. ZHANG Y, Wu H, Yu Z, Li L, et al
    Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    BMC Cancer. 2022;22:842.
    PubMed     Abstract available

  334. CHO B, Perez M, Jeffe DB, Kreuter MW, et al
    Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.
    BMC Cancer. 2022;22:837.
    PubMed     Abstract available

    July 2022
  335. LIU N, Yang DW, Wu YX, Xue WQ, et al
    Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: an up-to-date overview and comparison with those in Japan and South Korea.
    BMC Cancer. 2022;22:826.
    PubMed     Abstract available

  336. RO V, Jones T, Silverman T, McGuinness JE, et al
    Patient, primary care provider, and stakeholder perspectives on mammography screening frequency: lessons learned from a qualitative study.
    BMC Cancer. 2022;22:819.
    PubMed     Abstract available

  337. BRAHIM SM, Zein EE, Bonnet C, Hamed CT, et al
    Screening of BRCA1/2 variants in Mauritanian breast cancer patients.
    BMC Cancer. 2022;22:802.
    PubMed     Abstract available

  338. BHAKKAN-MAMBIR B, Deloumeaux J, Luce D
    Geographical variations of cancer incidence in Guadeloupe, French West Indies.
    BMC Cancer. 2022;22:783.
    PubMed     Abstract available

  339. DOS SANTOS RLB, Pepe VLE, Osorio-de-Castro CGS
    Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019.
    BMC Cancer. 2022;22:769.
    PubMed     Abstract available

  340. FONSECA MM, Alhassan T, Nisha Y, Koszycki D, et al
    Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
    BMC Cancer. 2022;22:774.
    PubMed     Abstract available

  341. TOAMA W, Wiederin J, Shanley R, Jewett P, et al
    Impact of pectoralis muscle loss on cardiac outcome and survival in Cancer patients who received anthracycline based chemotherapy: retrospective study.
    BMC Cancer. 2022;22:763.
    PubMed     Abstract available

  342. JIA L, Li G, Ma N, Zhang A, et al
    Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction.
    BMC Cancer. 2022;22:760.
    PubMed     Abstract available

    June 2022
  343. KHAN MA, Zheng M, Fu J, Tania M, et al
    Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro.
    BMC Cancer. 2022;22:707.
    PubMed     Abstract available

  344. PATULEIA SIS, Moelans CB, Koopman J, van Steenhoven JEC, et al
    Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?
    BMC Cancer. 2022;22:705.
    PubMed     Abstract available

  345. BORDE J, Laitman Y, Blumcke B, Niederacher D, et al
    Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    BMC Cancer. 2022;22:706.
    PubMed     Abstract available

  346. REIS J, Boavida J, Tran HT, Lyngra M, et al
    Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.
    BMC Cancer. 2022;22:702.
    PubMed     Abstract available

  347. HU K, Wang C, Luo C, Zheng H, et al
    Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts.
    BMC Cancer. 2022;22:680.
    PubMed     Abstract available

  348. WOLF J, Kurz S, Rothe T, Serpa M, et al
    Incidental irradiation of the regional lymph nodes during deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a dosimetric analysis.
    BMC Cancer. 2022;22:682.
    PubMed     Abstract available

  349. DUZENLI C, Chan EK, Bergman AM, Grahame S, et al
    A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: a study protocol for a multicentre phase III randomized controlled trial.
    BMC Cancer. 2022;22:673.
    PubMed     Abstract available

  350. DARBEHESHTI F, Kadkhoda S, Keshavarz-Fathi M, Razi S, et al
    Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    BMC Cancer. 2022;22:668.
    PubMed     Abstract available

  351. SEHOVIC E, Urru S, Chiorino G, Doebler P, et al
    Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection.
    BMC Cancer. 2022;22:634.
    PubMed     Abstract available

  352. YELLAPU NK, Ly T, Sardiu ME, Pei D, et al
    Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
    BMC Cancer. 2022;22:627.
    PubMed     Abstract available

  353. OMARINI C, Piacentini F, Sperduti I, Cerma K, et al
    T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.
    BMC Cancer. 2022;22:623.
    PubMed     Abstract available

  354. LI XF, Fu WF, Zhang J, Song CG, et al
    An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
    BMC Cancer. 2022;22:619.
    PubMed     Abstract available

  355. WANG Y, Song W, Zhou S, Chang S, et al
    The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
    BMC Cancer. 2022;22:618.
    PubMed     Abstract available

  356. LI X, An C, Zhang W
    Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy.
    BMC Cancer. 2022;22:614.
    PubMed     Abstract available

    May 2022
  357. AMORNSUPAK K, Thongchot S, Thinyakul C, Box C, et al
    HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2022;22:578.
    PubMed     Abstract available

  358. TSENG CH
    Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
    BMC Cancer. 2022;22:559.
    PubMed     Abstract available

  359. BENTLEY JR, Yu X, Karmarkar AM, Downer B, et al
    Feasibility and thematic analysis of narrative visualization materials with physical activity monitoring among breast cancer survivors.
    BMC Cancer. 2022;22:553.
    PubMed     Abstract available

  360. REN X, Song Y, Zhang Y, Wu H, et al
    Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    BMC Cancer. 2022;22:548.
    PubMed     Abstract available

  361. KOHLS M, Freisling H, Charvat H, Soerjomataram I, et al
    Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study.
    BMC Cancer. 2022;22:546.
    PubMed     Abstract available

  362. SAYAN M, Eren MF, Kilic SS, Kotek A, et al
    Utilization of radiation therapy and predictors of noncompliance among Syrian refugees in Turkey.
    BMC Cancer. 2022;22:532.
    PubMed     Abstract available

  363. ZENG X, Jiang S, Ruan S, Zhu L, et al
    Cardiovascular risk factors and breast cancer incidence in a large middle-aged cohort study.
    BMC Cancer. 2022;22:534.
    PubMed     Abstract available

  364. ZHOU J, Sun X, Zhang X, Yang H, et al
    miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer.
    BMC Cancer. 2022;22:533.
    PubMed     Abstract available

  365. NGUYEN VAN LONG F, Lardy-Cleaud A, Carene D, Rossoni C, et al
    Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.
    BMC Cancer. 2022;22:526.
    PubMed     Abstract available

  366. ESER K, Onder AH, Sezer E, Cil T, et al
    Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
    BMC Cancer. 2022;22:516.
    PubMed     Abstract available

  367. BROWN J, Scardo S, Method M, Schlauch D, et al
    A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
    BMC Cancer. 2022;22:502.
    PubMed     Abstract available

  368. ROUX A, Cholerton R, Sicsic J, Moumjid N, et al
    Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.
    BMC Cancer. 2022;22:507.
    PubMed     Abstract available

  369. MITAL S, Nguyen HV
    Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
    BMC Cancer. 2022;22:501.
    PubMed     Abstract available

  370. MCLAUGHLIN PMJ, Klar M, Zwimpfer TA, Dutilh G, et al
    Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
    BMC Cancer. 2022;22:508.
    PubMed     Abstract available

  371. DELRIEU L, Hamy AS, Coussy F, Kassara A, et al
    Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.
    BMC Cancer. 2022;22:493.
    PubMed     Abstract available

    April 2022
  372. LI J, Li H, Guan L, Lu Y, et al
    The value of preoperative sentinel lymph node contrast-enhanced ultrasound for breast cancer: a large, multicenter trial.
    BMC Cancer. 2022;22:455.
    PubMed     Abstract available

  373. LEE HJ, Choi CH
    Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
    BMC Cancer. 2022;22:446.
    PubMed     Abstract available

  374. CHEN H, Luo H, Wang J, Li J, et al
    Identification of a pyroptosis-related prognostic signature in breast cancer.
    BMC Cancer. 2022;22:429.
    PubMed     Abstract available

  375. WINTRAECKEN VM, Vulik S, de Wild S, Dirksen C, et al
    A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer.
    BMC Cancer. 2022;22:426.
    PubMed     Abstract available

  376. HE Y, Han SB, Liu Y, Zhang JJ, et al
    Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer.
    BMC Cancer. 2022;22:411.
    PubMed     Abstract available

  377. LUNARDI M, Al-Habbaa A, Abdelshafy M, Davey MG, et al
    Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review.
    BMC Cancer. 2022;22:396.
    PubMed     Abstract available

  378. GONCALVES R, Mota BS, Sobreira-Lima B, Ricci MD, et al
    The oncological safety of autologous fat grafting: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:391.
    PubMed     Abstract available

  379. XIE Y, Gou Q, Zhang Y, Xie K, et al
    Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China.
    BMC Cancer. 2022;22:385.
    PubMed     Abstract available

  380. HOU C, Xu B, Hao Y, Yang D, et al
    Development and validation of polygenic risk scores for prediction of breast cancer and breast cancer subtypes in Chinese women.
    BMC Cancer. 2022;22:374.
    PubMed     Abstract available

  381. ZERELLA MA, Zaffaroni M, Ronci G, Dicuonzo S, et al
    Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study - a phase I/II clinical trial protocol.
    BMC Cancer. 2022;22:358.
    PubMed     Abstract available

  382. REYNOLDS LM, Cavadino A, Chin S, Little Z, et al
    The benefits and acceptability of virtual reality interventions for women with metastatic breast cancer in their homes; a pilot randomised trial.
    BMC Cancer. 2022;22:360.
    PubMed     Abstract available

    March 2022
  383. ZHU GL, Xu C, Yang KB, Tang SQ, et al
    Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization.
    BMC Cancer. 2022;22:353.
    PubMed     Abstract available

  384. SHEWELL LK, Day CJ, Kutasovic JR, Abrahams JL, et al
    N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.
    BMC Cancer. 2022;22:334.
    PubMed     Abstract available

  385. AMITANI M, Oba T, Kiyosawa N, Morikawa H, et al
    Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
    BMC Cancer. 2022;22:327.
    PubMed     Abstract available

  386. MANOUCHEHRI E, Taghipour A, Ebadi A, Homaei Shandiz F, et al
    Understanding breast cancer risk factors: is there any mismatch between laywomen perceptions and expert opinions.
    BMC Cancer. 2022;22:309.
    PubMed     Abstract available

  387. MARTEI YM, Dauda B, Vanderpuye V
    Correction: Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
    BMC Cancer. 2022;22:306.

  388. DEN DEKKER BM, Christenhusz A, van Dalen T, Jongen LM, et al
    A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial.
    BMC Cancer. 2022;22:305.
    PubMed     Abstract available

  389. HAN B, Zhen F, Zheng XS, Hu J, et al
    Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.
    BMC Cancer. 2022;22:297.
    PubMed     Abstract available

  390. SADAQA D, Farraj A, Naseef H, Alsaid H, et al
    Risk of developing depression among breast cancer patients in Palestine.
    BMC Cancer. 2022;22:295.
    PubMed     Abstract available

  391. CHAN KS, Cheung SM, Senn N, Husain E, et al
    Peri-tumoural spatial distribution of lipid composition and tubule formation in breast cancer.
    BMC Cancer. 2022;22:285.
    PubMed     Abstract available

  392. BHARDWAJ A, Embury MD, Ju Z, Wang J, et al
    Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer.
    BMC Cancer. 2022;22:282.
    PubMed     Abstract available

  393. JUNG H, Lu M, Quan ML, Cheung WY, et al
    New method for determining breast cancer recurrence-free survival using routinely collected real-world health data.
    BMC Cancer. 2022;22:281.
    PubMed     Abstract available

  394. DUAN F, Zhong M, Ma Y, Song C, et al
    The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).
    BMC Cancer. 2022;22:271.
    PubMed     Abstract available

  395. WANG C, Zhou Y, Lin Y, Mao F, et al
    Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    BMC Cancer. 2022;22:269.
    PubMed     Abstract available

  396. YE F, Bian L, Wen J, Yu P, et al
    Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    BMC Cancer. 2022;22:261.
    PubMed     Abstract available

  397. YANG PJ, Hou MF, Ou-Yang F, Tsai EM, et al
    Association of early-onset breast cancer with body mass index, menarche, and menopause in Taiwan.
    BMC Cancer. 2022;22:259.
    PubMed     Abstract available

  398. YANG TO, Cairns BJ, Pirie K, Green J, et al
    Body size in early life and the risk of postmenopausal breast cancer.
    BMC Cancer. 2022;22:232.
    PubMed     Abstract available

  399. CHEN YB, Bao HS, Hu TT, He Z, et al
    Comparison of comfort and complications of Implantable Venous Access Port (IVAP) with ultrasound guided Internal Jugular Vein (IJV) and Axillary Vein/Subclavian Vein (AxV/SCV) puncture in breast cancer patients: a randomized controlled study.
    BMC Cancer. 2022;22:248.
    PubMed     Abstract available

  400. HORIMOTO Y, Ishizuka Y, Ueki Y, Higuchi T, et al
    Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.
    BMC Cancer. 2022;22:242.
    PubMed     Abstract available

  401. LOMAN BR, Russart KLG, Grant CV, Lynch AJ, et al
    Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation.
    BMC Cancer. 2022;22:245.
    PubMed     Abstract available

  402. TANG R, Deng JP, Zhang L, Zhang WW, et al
    Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    BMC Cancer. 2022;22:234.
    PubMed     Abstract available

  403. ZHANG X, Mu X, Huang O, Wang Z, et al
    ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.
    BMC Cancer. 2022;22:226.
    PubMed     Abstract available

    February 2022
  404. PARK SY, Lim JW
    Cognitive behavioral therapy for reducing fear of cancer recurrence (FCR) among breast cancer survivors: a systematic review of the literature.
    BMC Cancer. 2022;22:217.
    PubMed     Abstract available

  405. ELBIAD O, Laraqui A, El Boukhrissi F, Mounjid C, et al
    Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    BMC Cancer. 2022;22:208.
    PubMed     Abstract available

  406. MARTEI YM, Dauda B, Vanderpuye V
    Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
    BMC Cancer. 2022;22:203.
    PubMed     Abstract available

  407. SARKER R, Islam MS, Moonajilin MS, Rahman M, et al
    Effectiveness of educational intervention on breast cancer knowledge and breast self-examination among female university students in Bangladesh: a pre-post quasi-experimental study.
    BMC Cancer. 2022;22:199.
    PubMed     Abstract available

  408. JUNG JG, Ahn SH, Lee S, Kim EK, et al
    No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
    BMC Cancer. 2022;22:189.
    PubMed     Abstract available

  409. CLOUD AS, Vargheese AM, Gunewardena S, Shimak RM, et al
    Loss of REST in breast cancer promotes tumor progression through estrogen sensitization, MMP24 and CEMIP overexpression.
    BMC Cancer. 2022;22:180.
    PubMed     Abstract available

  410. AMBROSIO MR, Magli E, Caliendo G, Sparaco R, et al
    Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells.
    BMC Cancer. 2022;22:171.
    PubMed     Abstract available

  411. GOTO W, Kashiwagi S, Kamei Y, Watanabe C, et al
    Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.
    BMC Cancer. 2022;22:167.
    PubMed     Abstract available

  412. VITALE SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, et al
    The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
    BMC Cancer. 2022;22:165.
    PubMed     Abstract available

  413. BRAHIMETAJ R, Willekens I, Massart A, Forsyth R, et al
    Improved automated early detection of breast cancer based on high resolution 3D micro-CT microcalcification images.
    BMC Cancer. 2022;22:162.
    PubMed     Abstract available

  414. LIAO Q, Deng D, Xie Q, Gong X, et al
    Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study.
    BMC Cancer. 2022;22:152.
    PubMed     Abstract available

  415. ANDREWS C, Childers TC, Wiseman KD, Lawhon V, et al
    Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.
    BMC Cancer. 2022;22:141.
    PubMed     Abstract available

  416. BU X, Jin C, Fan R, Cheng ASK, et al
    Unmet needs of 1210 Chinese breast cancer survivors and associated factors: a multicentre cross-sectional study.
    BMC Cancer. 2022;22:135.
    PubMed     Abstract available

  417. HEINIG M, Heinze F, Schwarz S, Haug U, et al
    Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery-an analysis of German claims data.
    BMC Cancer. 2022;22:130.
    PubMed     Abstract available

    January 2022
  418. GRAY LA, Hernandez Alava M, Wailoo AJ
    Correction to: Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    BMC Cancer. 2022;22:112.

  419. VAN EIJK M, Vermunt MAC, van Werkhoven E, Wilthagen EA, et al
    The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    BMC Cancer. 2022;22:104.
    PubMed     Abstract available

  420. ZHONG YM, Tong F, Shen J
    Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:102.
    PubMed     Abstract available

  421. GANESAMOORTHY D, Robertson AJ, Chen W, Hall MB, et al
    Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
    BMC Cancer. 2022;22:85.
    PubMed     Abstract available

  422. RAINEY L, van der Waal D, Donnelly LS, Southworth J, et al
    Women's health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations.
    BMC Cancer. 2022;22:69.
    PubMed     Abstract available

  423. SALAS M, Mordin M, Castro C, Islam Z, et al
    Health-related quality of life in women with breast cancer: a review of measures.
    BMC Cancer. 2022;22:66.
    PubMed     Abstract available

  424. TAKAMIZAWA S, Shimoi T, Satomi-Tsushita N, Yazaki S, et al
    Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
    BMC Cancer. 2022;22:64.
    PubMed     Abstract available

  425. ZHOU K, Ning F, Wang W, Li X, et al
    The mediator role of resilience between psychological predictors and health-related quality of life in breast cancer survivors: a cross-sectional study.
    BMC Cancer. 2022;22:57.
    PubMed     Abstract available

  426. EKSTROM K, Crescitelli R, Petursson HI, Johansson J, et al
    Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer.
    BMC Cancer. 2022;22:50.
    PubMed     Abstract available

  427. RAUTENBERG T, Hodgkinson B, Zerwes U, Downes M, et al
    Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer.
    BMC Cancer. 2022;22:52.
    PubMed     Abstract available

  428. VACHENC S, Gobbo J, Moujarrebe SE, Desmoulins I, et al
    OncoSNIPE(R) Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
    BMC Cancer. 2022;22:41.
    PubMed     Abstract available

  429. WANG S, Jiang H, Zheng C, Gu M, et al
    Secretion of BMP-2 by tumor-associated macrophages (TAM) promotes microcalcifications in breast cancer.
    BMC Cancer. 2022;22:34.
    PubMed     Abstract available

  430. OZAKI Y, Aoyama Y, Masuda J, Inagaki L, et al
    Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
    BMC Cancer. 2022;22:36.
    PubMed     Abstract available

  431. CHITAPANARUX I, Onchan W, Wongmaneerung P, Somwangprasert A, et al
    Integration of breast cancer care in a middle-income country: learning from Suandok Breast Cancer Network (SBCN).
    BMC Cancer. 2022;22:26.
    PubMed     Abstract available

  432. LI L, Ai L, Jia L, Zhang L, et al
    High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
    BMC Cancer. 2022;22:29.
    PubMed     Abstract available

  433. NAKAMOTO S, Watanabe J, Ohtani S, Morita S, et al
    Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
    BMC Cancer. 2022;22:31.
    PubMed     Abstract available

  434. BOUFERRAA Y, Haibe Y, Chedid A, Jabra E, et al
    The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
    BMC Cancer. 2022;22:27.
    PubMed     Abstract available

  435. LEE YJ, Kim Y, Choi BB, Kim JR, et al
    The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer.
    BMC Cancer. 2022;22:12.
    PubMed     Abstract available

  436. HAJJ A, Chamoun R, Salameh P, Khoury R, et al
    Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors.
    BMC Cancer. 2022;22:16.
    PubMed     Abstract available

  437. ESPOSITO MV, Fosso B, Nunziato M, Casaburi G, et al
    Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women.
    BMC Cancer. 2022;22:30.
    PubMed     Abstract available

  438. LAI Z, Brosnan M, Sokol ES, Xie M, et al
    Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    BMC Cancer. 2022;22:13.
    PubMed     Abstract available

    December 2021
  439. BARTMANN C, Fischer LM, Hubner T, Muller-Reiter M, et al
    The effects of the COVID-19 pandemic on psychological stress in breast cancer patients.
    BMC Cancer. 2021;21:1356.
    PubMed     Abstract available

  440. RADES D, Narvaez CA, Dziggel L, Janssen S, et al
    A prospective interventional study investigating sleep disorders prior to and during adjuvant radiotherapy for breast cancer.
    BMC Cancer. 2021;21:1349.
    PubMed     Abstract available

  441. OLSEN M, Fischer K, Bossuyt PM, Goetghebeur E, et al
    Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification.
    BMC Cancer. 2021;21:1351.
    PubMed     Abstract available

  442. KARSONO R, Haryono SJ, Karsono B, Harahap WA, et al
    ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.
    BMC Cancer. 2021;21:1348.
    PubMed     Abstract available

  443. RUFF GL, Murphy KE, Smith ZR, Vertino PM, et al
    Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation.
    BMC Cancer. 2021;21:1342.
    PubMed     Abstract available

  444. PARK HL, Chang J, Haridass V, Wang SS, et al
    Mammography screening and mortality by risk status in the California teachers study.
    BMC Cancer. 2021;21:1341.
    PubMed     Abstract available

  445. ZHANG MK, Wang B, Li SY, Liu G, et al
    TGF-beta1 and its signal molecules: are they correlated with the elasticity characteristics of breast lesions?
    BMC Cancer. 2021;21:1336.
    PubMed     Abstract available

  446. LIN S, Mo H, Li Y, Guan X, et al
    Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
    BMC Cancer. 2021;21:1330.
    PubMed     Abstract available

  447. XU D, Zhang Y, Jin F
    The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
    BMC Cancer. 2021;21:1321.
    PubMed     Abstract available

  448. LI F, Sun H, Li Y, Bai X, et al
    High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
    BMC Cancer. 2021;21:1305.
    PubMed     Abstract available

  449. ZHANG J, Jiang H, Zhang J, Bao G, et al
    Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
    BMC Cancer. 2021;21:1301.
    PubMed     Abstract available

  450. GIACOMELLI C, Jung J, Wachter A, Ibing S, et al
    Coordinated regulation of WNT/beta-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    BMC Cancer. 2021;21:1296.
    PubMed     Abstract available

  451. KEPESIDIS KV, Bozic-Iven M, Huber M, Abdel-Aziz N, et al
    Breast-cancer detection using blood-based infrared molecular fingerprints.
    BMC Cancer. 2021;21:1287.
    PubMed     Abstract available

  452. JIANG H, Meng L, Zhang H, Dai X, et al
    Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
    BMC Cancer. 2021;21:1284.
    PubMed     Abstract available

    November 2021
  453. MAZZONI AS, Brooke HL, Berntsen S, Nordin K, et al
    Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of the Phys-Can RCT.
    BMC Cancer. 2021;21:1272.
    PubMed     Abstract available

  454. MASUDA N, Tamura K, Yasojima H, Shimomura A, et al
    Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
    BMC Cancer. 2021;21:1269.
    PubMed     Abstract available

  455. XIN Y, Shen G, Zheng Y, Guan Y, et al
    Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1261.
    PubMed     Abstract available

  456. KLEIN I, Kalichman L, Chen N, Susmallian S, et al
    A comprehensive approach to risk factors for upper arm morbidities following breast cancer treatment: a prospective study.
    BMC Cancer. 2021;21:1251.
    PubMed     Abstract available

  457. SHI Y, Liu C
    Circular RNA hsa_circ_0043278 inhibits breast cancer progression via the miR-455-3p/EI24 signalling pathway.
    BMC Cancer. 2021;21:1249.
    PubMed     Abstract available

  458. GRAY LA, Hernandez Alava M, Wailoo AJ
    Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    BMC Cancer. 2021;21:1237.
    PubMed     Abstract available

  459. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
    Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study.
    BMC Cancer. 2021;21:1210.
    PubMed     Abstract available

  460. CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
    Correction to: Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
    BMC Cancer. 2021;21:1198.

  461. MIGEOTTE A, Dufour V, van Maanen A, Berliere M, et al
    Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
    BMC Cancer. 2021;21:1204.
    PubMed     Abstract available

  462. WANG Z, Hu S, Li X, Liu Z, et al
    MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
    BMC Cancer. 2021;21:1188.
    PubMed     Abstract available

  463. ZHAO XR, Fang H, Tang Y, Hu ZH, et al
    POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial.
    BMC Cancer. 2021;21:1185.
    PubMed     Abstract available

  464. VAN PARIJS H, Vinh-Hung V, Fontaine C, Storme G, et al
    Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.
    BMC Cancer. 2021;21:1177.
    PubMed     Abstract available

  465. WIJERATNE DT, Gunasekera S, Booth CM, Promod H, et al
    Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry.
    BMC Cancer. 2021;21:1175.
    PubMed     Abstract available

  466. XIE Y, Gong C, Zhang J, Wang L, et al
    Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
    BMC Cancer. 2021;21:1174.
    PubMed     Abstract available

    October 2021
  467. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
    Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
    BMC Cancer. 2021;21:1168.
    PubMed     Abstract available

  468. TANG W, Xu F, Zhao M, Zhang S, et al
    Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
    BMC Cancer. 2021;21:1160.
    PubMed     Abstract available

  469. CREEDEN JF, Nanavaty NS, Einloth KR, Gillman CE, et al
    Homologous recombination proficiency in ovarian and breast cancer patients.
    BMC Cancer. 2021;21:1154.
    PubMed     Abstract available

  470. SAJJADI E, Venetis K, Piciotti R, Gambini D, et al
    Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
    BMC Cancer. 2021;21:1152.
    PubMed     Abstract available

  471. KIM K, Kim IJ, Pak K, Kang T, et al
    Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative (18)F-FDG PET-CT in breast cancer: a retrospective cross-sectional study.
    BMC Cancer. 2021;21:1151.
    PubMed     Abstract available

  472. AL RABADI LS, Cook MM, Kaempf AJ, Saraceni MM, et al
    Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    BMC Cancer. 2021;21:1150.
    PubMed     Abstract available

  473. SHIMOI T, Hashimoto J, Sudo K, Shimomura A, et al
    Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
    BMC Cancer. 2021;21:1131.
    PubMed     Abstract available

  474. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.
    BMC Cancer. 2021;21:1129.
    PubMed     Abstract available

  475. BERTOZZI S, Londero AP, Viola L, Orsaria M, et al
    TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.
    BMC Cancer. 2021;21:1118.
    PubMed     Abstract available

  476. MERINO T, Pinto MP, Orellana MP, Martinez G, et al
    Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
    BMC Cancer. 2021;21:1114.
    PubMed     Abstract available

  477. AHSBERG K, Gardfjell A, Nimeus E, Ryden L, et al
    The PROCEM study protocol: Added value of preoperative contrast-enhanced mammography in staging of malignant breast lesions - a prospective randomized multicenter study.
    BMC Cancer. 2021;21:1115.
    PubMed     Abstract available

  478. HE Y, Tao Q, Zhou F, Si Y, et al
    The relationship between dairy products intake and breast cancer incidence: a meta-analysis of observational studies.
    BMC Cancer. 2021;21:1109.
    PubMed     Abstract available

  479. KIRKHAM AA, King K, Joy AA, Pelletier AB, et al
    Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise
    BMC Cancer. 2021;21:1093.
    PubMed     Abstract available

  480. TSUKAMOTO F, Arihiro K, Takahashi M, Ito KI, et al
    Multicenter retrospective study on the use of Curebest 95GC Breast for estrogen receptor-positive and node-negative early breast cancer.
    BMC Cancer. 2021;21:1077.
    PubMed     Abstract available

    September 2021
  481. LEE J, Jung JH, Kim WW, Kang B, et al
    Short-term serial assessment of electronic patient-reported outcome for depression and anxiety in breast Cancer.
    BMC Cancer. 2021;21:1065.
    PubMed     Abstract available

  482. LIN Y, Zhou X, Peng W, Wu J, et al
    Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
    BMC Cancer. 2021;21:1062.
    PubMed     Abstract available

  483. ABEBE E, Tollesa T, Assefa M, Tilahun Z, et al
    Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: an institution-based comparative cross-sectional study.
    BMC Cancer. 2021;21:1052.
    PubMed     Abstract available

  484. AKINYEMIJU T, Jones K, Gupta A, Oyekunle T, et al
    Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study.
    BMC Cancer. 2021;21:1051.
    PubMed     Abstract available

  485. RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
    Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
    BMC Cancer. 2021;21:1055.
    PubMed     Abstract available

  486. LIU J, Yin J, Liu Y, Xu Z, et al
    Characteristics of 1270 Chinese sibling pairs with cancer.
    BMC Cancer. 2021;21:1027.
    PubMed     Abstract available

  487. DIMITROVA D, Naghavi B, Richter R, Nasser S, et al
    Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
    BMC Cancer. 2021;21:1018.
    PubMed     Abstract available

  488. AMAYA C, Luo S, Baigorri J, Baucells R, et al
    Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
    BMC Cancer. 2021;21:981.
    PubMed     Abstract available

    August 2021
  489. TAVARES MC, Sampaio CD, Lima GE, Andrade VP, et al
    A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    BMC Cancer. 2021;21:901.
    PubMed     Abstract available

    July 2021
  490. JIANG J, Chen J, Li W, Li Y, et al
    Inter-observer variations of the tumor bed delineation for patients after breast conserving surgery in preoperative magnetic resonance and computed tomography scan fusion.
    BMC Cancer. 2021;21:838.
    PubMed     Abstract available

  491. LAMBERT P, Pitz M, Singh H, Decker K, et al
    Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province : Using algorithms to determine breast and colorectal cancer recurrence.
    BMC Cancer. 2021;21:763.
    PubMed     Abstract available

    June 2021
  492. YOO TK, Park SH, Do Han K, Chae BJ, et al
    Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.
    BMC Cancer. 2021;21:735.
    PubMed     Abstract available

  493. GUO L, Xie G, Wang R, Yang L, et al
    Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
    BMC Cancer. 2021;21:717.
    PubMed     Abstract available

  494. BAKOS B, Kiss A, Arvai K, Szili B, et al
    Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden.
    BMC Cancer. 2021;21:706.
    PubMed     Abstract available

  495. YU J, Lin C, Huang J, Hong J, et al
    Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer.
    BMC Cancer. 2021;21:707.
    PubMed     Abstract available

  496. DHAKA B, Sabarinathan R
    Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
    BMC Cancer. 2021;21:669.
    PubMed     Abstract available

  497. KOTNIK U, Peterlin B, Lovrecic L
    Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
    BMC Cancer. 2021;21:665.
    PubMed     Abstract available

    May 2021
  498. ZHENG L, Zheng F, Xing Z, Zhang Y, et al
    Breast lesions excised via vacuum-assisted system: could we get any clues for B3 lesions before excision biopsy?
    BMC Cancer. 2021;21:633.
    PubMed     Abstract available

  499. KOTANI H, Terada M, Mori M, Horisawa N, et al
    Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
    BMC Cancer. 2021;21:548.
    PubMed     Abstract available

  500. YANG S, Bian J, George TJ, Daily K, et al
    The association between cognitive impairment and breast and colorectal cancer screening utilization.
    BMC Cancer. 2021;21:539.
    PubMed     Abstract available

  501. ZHOU X, Zheng Z, Li Y, Zhao W, et al
    The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study.
    BMC Cancer. 2021;21:536.
    PubMed     Abstract available

  502. YANG JR, Kuo WL, Yu CC, Chen SC, et al
    Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study.
    BMC Cancer. 2021;21:522.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.